To determine the relationship between CALCRL expression levels and the clinical features or prognosis of AML patients, 67 primary AML/ETO+ AML patients were enrolled, including 40 men and 27 women, with a median age of 35 (range, 15–57) years. The gene discussed is CALCRL; the disease is acute myeloid leukemia.